OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
The future of cardiac xenotransplantation	832
PPARα regulates the development and inflammation of vein graft lesions	581
Social disparities in COVID-19 prevention	542
FFR-guided PCI vs CABG surgery in multivessel CAD	532
Endomyocardial fibrosis: recent advances and future therapeutic targets	474
Epigenetic editing in cardiovascular medicine: moving beyond the hype	445
Electronic alerts can PROMPT guideline-directed care for HFrEF	400
α-Myosin-specific CD8+ T cells drive ICI-related myocarditis	343
Non-fatal MI as surrogate end point for all-cause or cardiovascular mortality	312
Physicians in the era of technology-enabled diagnostics	269
Smartwatch detection of left ventricular dysfunction	246
Immediate non-inferior to staged complete revascularization	233
Intravascular imaging improves outcomes	231
Targeting the adipose tissue to protect the heart	226
Truncated titin proteins in the pathophysiology of DCM	220
Cost-effective benefit of iron-replacement therapy	205
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	194
Antibody treatment to deplete transthyretin amyloid deposits in the heart	194
Pacing with respiratory sinus arrhythmia improves outcomes in heart failure	188
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	188
Basophils promote healing after MI	186
Limited benefit of triglyceride lowering with fibrates in statin-treated patients	177
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	173
Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling	170
PCI for stable angina	162

Base editing therapy corrects long QT syndrome in mice	162
Revealing the structure of the cardiac myosin filament	162
Mentorship in cardiology: building the mentoring relationship	153
Functional testing after PCI in high-risk patients	146
Oxygen and BP targets for OHCA	144
Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD	139
Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy	139
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	138
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	138
No benefit of β-blockers after myocardial infarction with preserved ejection fraction	136
Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy	129
LIPC variant in combined hypocholesterolaemia	127
No benefit of colchicine to prevent AF or myocardial injury after non-cardiac surgery	121
CAS and CEA have similar risks and benefits	119
Author Correction: Traction force microscopy of cardiomyocytes	116
Cardiac optogenetics: controlling the heart with light	114
Haematometabolism rewiring in atherosclerotic cardiovascular disease	109
Three different therapies to target PCSK9	108
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	108
Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention	104
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved	104
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease	97
Current and future applications of virtual reality technology for cardiac interventions	97
Guidelines to lower intake of added sugar are necessary and justified	94
A roadmap of strategies to support cardiovascular researchers: from policy to practice	93
Hidden disparities in the rising prevalence of bystander cardiopulmonary resuscitation	93
Iron deficiency and supplementation in heart failure	93
Strategies to prevent burnout in the cardiovascular health-care workforce	90
Publisher Correction: Cardiac involvement in the long-term implications of COVID-19	89
Universal flu vaccines: a shot at lifelong cardioprotection?	87
IRONMAN adds support for iron repletion in HF	87
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	84
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	81
Social determinants of atrial fibrillation	80
Pulsed-field ablation: a revolution in atrial fibrillation therapy	79
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	78
Hypertension in China: epidemiology and treatment initiatives	76
Injectable and conductive cardiac patch	76
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	74
Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?	73
The need for increased pragmatism in cardiovascular clinical trials	73
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction	68
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease	67
The use of new CRISPR tools in cardiovascular research and medicine	66
A fresh look at coronary microembolization	66
The spleen in ischaemic heart disease	64
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	63
Sex-related similarities and differences in responses to heart failure therapies	62
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	61
Travelling with heart failure: risk assessment and practical recommendations	61

Genetics and mechanisms of thoracic aortic disease	60
Macrophages in cardiac remodelling after myocardial infarction	59
Sit less and move more for cardiovascular health: emerging insights and opportunities	59
Blood pressure and its variability: classic and novel measurement techniques	56
Vascular endothelial cell development and diversity	55
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	55
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	54
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	54
AI outperforms sonographers at diagnosing cardiac function on echocardiography	52
Self-expanding valves more beneficial than balloon-expandable valves in patients with a small aortic annulus	52
Heterogeneity of the post-infarct epicardium	51
Innate lymphoid cells improve recovery of cardiac function after MI	50
A proteomic model shows potential as a surrogate end point for CVD risk	50
Ceramides aggravate atherosclerosis via G protein-coupled receptor signalling	50
Left atrial appendage occlusion	50
Abbreviating DAPT reduces the risk of bleeding	49
Macrophage OLFR2 activation is atherogenic	49
Sirtuin 2 protects against cardiac ageing	49
CD200 is an atheroprotective immune checkpoint	48
Mending broken hearts with the help of epigenetic remodellers	48
Resurgence of renal denervation for resistant hypertension	46
Blocking endothelial lipase raises HDL-C levels	45
The brain–heart axis: integrative cooperation of neural, mechanical and biochemical pathways	44
Inhibiting aldosterone synthase reduces blood pressure	43
Cryoballoon ablation reduces AF progression	42
Promising findings for cell therapy in HFrEF	42
Sodium and potassium intake for CV health	41
Ablation plus pacing strategy reduces mortality in patients with AF and HF	41
Haemostatic functions of novel synthetic platelets	39
Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures	38
Dietary patterns to promote cardiometabolic health	38
Levothyroxine supplementation does not improve heart transplantation from brain-dead donors	37
Remuscularizing the failing heart in primates	37
The cardiac parasympathetic system has two parallel circuits	37
AI-driven evolution of precision population cardiovascular health in cities	37
Complete revascularization in MI: role in older patients and optimal timing	37
Age-induced senescence impairs the neurovascular interface in the heart	35
Long COVID and cardiovascular disease: a learning health system approach	34
New insights into OCT-guided PCI	34
Vitamin K antagonists for RHD-associated AF	33
Polypills for the secondary prevention of MACE	31
Cardiovascular benefits of statins outweigh small risk of muscle pain	30
ASGR1 inhibition stimulates cholesterol excretion	29
Artificially transplanted mitochondria in endothelial cells promote mitophagy	27
A newly identified gut hormone suppresses cholesterol production in the liver	26
Selective JAG1–NOTCH3 targeting shows potential for treating PAH	26
Anti-IL-1β therapy lowers leukocyte supply and uptake in atherosclerosis	25
Glucocorticoid receptor inhibition promotes cardiac repair after MI	25
Weight loss from surgery or drug therapy reduces blood pressure	24
DYRK1A gene linked to heart defects in Down syndrome	24
Reply to ‘Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease’	23
Clinical implications of perioperative and periprocedural myocardial infarction	23
Explaining how a cardiac reflex causes syncope	23
Role of sex hormones in cardiovascular diseases	22
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	22
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	22
Alternative defibrillation strategies improve outcomes	20
Monocytes migrate to the brain after MI to promote deep sleep to aid cardiac healing	20
Roadmap for alleviating the manifestations of ageing in the cardiovascular system	19
An all-virtual clinical trial to assess a heart failure drug	19
Obstructive sleep apnoea heterogeneity and cardiovascular disease	18
Effective CRISPR modulation of complex non-coding RNA loci	18
The rapid delayed-rectifier potassium current: a biophysical basis for cardiac repolarization and arrhythmia	18
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?	17
Hallmarks of cardiovascular ageing	17
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	17
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	17
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	16
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes	16
Update on the pathophysiology and medical treatment of peripheral artery disease	16
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism	16
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	15
Tackling inflammation in atherosclerosis	15
β-blockers after MI: does ABYSS confirm REDUCEd use after all?	15
Pathophysiological insights into HFpEF from studies of human cardiac tissue	15
Detection of subclinical hypertrophic cardiomyopathy	15